9 completed, 4 recruiting, 1 unknown, 1 withdrawn. 7 Phase 1, 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Recruiting 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 2 | Completed 2 |
Follow Multiple Endocrine Neoplasia Type 2a: new trials by email Literature Review of Multiple Endocrine Neoplasia Type 2a trials Research Report on Multiple Endocrine Neoplasia Type 2a
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract | Recruiting | Universidad Nacional Autonoma de Mexico | 750 | 2022-08-03 | 2024-07-26 | |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer BNT116, Cemiplimab, Docetaxel - Non-Small Cell Lung Cancer | Phase 1 | Recruiting | BioNTech SE | 320 | 2022-06-17 | 2026-07-22 |
| Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer Liquid biopsy - Lung Cancer | Unknown | University of Milano Bicocca | 20 | 2021-12-12 | 2023-10-13 | |
| Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors BOS172738 - Advanced Nonhaematologic Malignancies | Phase 1 | Completed | Boston Pharmaceuticals | 117 | 2018-12-12 | 2023-10-30 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer Alectinib, Crizotinib - Neoplasms | Phase 3 | Completed | Hoffmann-La Roche | 50 | 2017-07-05 | 2026-10-09 |
| A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers GSK3352589, Matching Placebo - Irritable Bowel Syndrome | Phase 1 | Completed | GlaxoSmithKline | 68 | 2017-05-17 | 2019-08-09 |
| Familial Investigations of Childhood Cancer Predisposition Acute Leukemia, Adenomatous Polyposis | Recruiting | St. Jude Children's Research Hospital | 1500 | 2017-04-06 | 2026-06-17 | |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 590 | 2017-03-17 | 2025-05-31 |
| A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers GSK3179106, Placebo - Irritable Bowel Syndrome | Phase 1 | Completed | GlaxoSmithKline | 16 | 2015-11-26 | 2017-05-08 |
| Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2 | Completed | National Cancer Institute (NCI) | 150 | 2010-07-05 | 2018-04-05 | |
| Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Rare Disorders, Undiagnosed Disorders | Recruiting | Sanford Health | 20000 | 2010-07-01 | 2026-10-28 | |
| Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer Vandetanib - Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2007-07-20 | 2020-12-22 |
| Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer Sorafenib Tosylate - Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2006-11-03 | 2024-02-06 |
| Cinacalcet to Treat Familial Primary Hyperparathyroidism Parathyroid hormone testing, Serum calcium testing - Hypercalcemia, Familial Primary Hyperparathyroidism | Phase 3 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 25 | 2006-05-09 | 2017-07-02 |
Carcinoma, Medullary (8) · Carcinoma, Non-Small-Cell Lung (4) · Multiple Endocrine Neoplasia Type 1 (4) · Multiple Endocrine Neoplasia Type 2b (4) · Multiple Endocrine Neoplasia (3) · Neuroendocrine Tumors (3) · Pheochromocytoma (3) · Carney Complex (2) · Colorectal Neoplasms, Hereditary Nonpolyposis (2) · Hamartoma Syndrome, Multiple (2) · Insulinoma (2) · Irritable Bowel Syndrome (2) · Li-Fraumeni Syndrome (2) · Lung Neoplasms (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Genetic Diseases, Inborn (15) · Neoplasms, Multiple Primary (15) · Neoplastic Syndromes, Hereditary (15) · Endocrine Gland Neoplasms (14) · Endocrine System Diseases (14) · Neoplasms by Site (14) · Neoplasms (13) · Multiple Endocrine Neoplasia (12) · Neoplasms by Histologic Type (9) · Adenocarcinoma (8) · Carcinoma (8) · Neoplasms, Ductal, Lobular, and Medullary (8) · Neoplasms, Germ Cell and Embryonal (8) · Neoplasms, Glandular and Epithelial (8)
Antibodies, Bispecific (1) · Capecitabine (1) · Carboplatin (1) · Crizotinib (1) · Docetaxel (1) · GSK3352589 (1) · Liquid Biopsy (1) · Paclitaxel (1) · Sorafenib (1) · Temozolomide (1) · Vascular Endothelial Growth Factor A (1) · alectinib (1) · cemiplimab (1) · osimertinib (1) · pralsetinib (1)
National Cancer Institute (NCI) (3) · GlaxoSmithKline (2) · Hoffmann-La Roche (2) · BioNTech SE (1) · Boston Pharmaceuticals (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Sanford Health (1) · St. Jude Children's Research Hospital (1) · Universidad Nacional Autonoma de Mexico (1) · University of Milano Bicocca (1) · Vanderbilt-Ingram Cancer Center (1)
United States (10) · Spain (4) · Australia (3) · France (3) · Hong Kong (3) · Italy (3) · South Korea (3) · Belgium (2) · Germany (2) · Poland (2) · Taiwan (2) · Turkey (Türkiye) (2) · United Kingdom (2) · China (1) · Hungary (1)
Antonio T Fojo, M.D. (1) · Bhavana Konda (1) · Brigitte C Widemann, M.D. (1) · Diego Cortinovis, MD (1) · Jordan Berlin, M.D. (1) · Kim E. Nichols, MD (1) · Luca Mologni, PhD (1)
PMID 23766359, PMID 24617713, PMID 25972901, PMID 29187393, PMID 30277655, PMID 33606922, PMID 34118197, PMID 34118198, PMID 35715405, PMID 35962206, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 40639400, PMID 41886723
2016 (1), 2017 (1), 2018 (1), 2023 (1), N01CM00070 (1), N01CM62207 (1), P30CA016058 (1)